SHARE THIS ARTICLE
Saxenda
Saxenda vs Ozempic – Comparing Weight Loss Treatments
May 28, 2025
A systematic review in The BMJ revealed that behavioral weight management interventions typically result in modest but meaningful weight loss—about 2.3 kg at 12 months and 1.8 kg at 24 months. While lifestyle changes remain the cornerstone of healthy weight control, many individuals find they need additional help to reach their goals, especially when sustained weight loss is elusive.
Saxenda and Ozempic are two pharmaceutical options that have gained rapid popularity for their ability to regulate appetite and improve blood sugar control, resulting in significant weight reduction. Despite similarities, these medications differ in dosage, administration methods, and their overall impact on weight loss journeys.
In this article, we’ll dive into a detailed comparison of Saxenda vs Ozempic, exploring how they work, their effectiveness, safety profiles, and practical considerations, equipping you with the knowledge to choose the treatment best suited to your needs.
Key Takeaways
- Saxenda (liraglutide) and Ozempic (semaglutide) are both GLP-1 receptor agonists that help regulate appetite and slow gastric emptying, aiding weight loss.
- Saxenda requires daily injections, while Ozempic patients should administer it once a week. This may improve patient adherence.
- Clinical trials show that Ozempic generally leads to greater weight loss (10-15% of body weight) compared to Saxenda (5-8%) over similar periods.
- Saxenda has FDA approval for weight management. On the other hand, Ozempic has approval for type 2 diabetes, but doctors may prescribe it off-label for weight loss.
- Both medications have similar common side effects, including nausea, vomiting, diarrhea, and constipation, with Ozempic potentially posing a higher risk of hypoglycemia in diabetic patients.
- Both carry warnings for thyroid tumors and potential pancreatitis risk, requiring careful medical supervision.
- Patients should be cautious of counterfeit products and always obtain medications from legitimate sources.
About: Trusted by over 2,000+ global clients since 2014, Maylips has become a leading supplier of cosmetic, skincare, and orthopedic products for medical and aesthetic professionals. Maylips offers a wide range of authentic brand-name products at competitive wholesale prices, sourced from around the world. If you’re looking to buy Saxenda online, contact our sales team for guidance.
Pharmacological Profiles of Saxenda and Ozempic
Saxenda (liraglutide) is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) specifically approved for chronic weight management. It mimics the natural GLP-1 hormone by slowing gastric emptying and reducing appetite, helping patients feel full sooner and eat less. Saxenda’s relatively short half-life requires daily subcutaneous injections, which can pose adherence challenges for some users.
In contrast, Ozempic (semaglutide) is also a GLP-1 RA but boasts a much longer half-life, allowing for once-weekly injections. While primarily approved for treating type 2 diabetes, Ozempic is increasingly prescribed off-label for weight loss due to its potent appetite suppression and favorable metabolic effects.
Both medications influence hunger cues in the brain and delay gastric emptying, yet their distinct dosing schedules and pharmacokinetics may affect patient preference and the likelihood of long-term success.
Saxenda vs Ozempic: Efficacy in Weight Management
The STEP 8 trial directly compared semaglutide (Ozempic) and liraglutide (Saxenda) for weight loss outcomes. Results indicated that semaglutide led to significantly greater weight reduction at both 20 and 68 weeks. Clinical studies suggest that Ozempic users can expect to lose approximately 10-15% of their body weight, while Saxenda users typically see a 5-8% weight loss within the same timeframe.
Real-world evidence aligns with these findings, with many patients on Ozempic reporting noticeable appetite suppression and weight loss within weeks of treatment initiation. However, it’s important to note that Ozempic is not yet FDA-approved specifically for weight management, which may affect access and insurance coverage.
Saxenda vs Ozempic: Safety and Tolerability
Understanding Saxenda side effects and how they differ from Ozempic’s is critical for making informed treatment decisions. Both medications carry important safety considerations that patients should discuss with their healthcare providers.
Common side effects include nausea, vomiting, diarrhea, and constipation, often related to the gastrointestinal adjustments these drugs induce.
- Hypoglycemia Risk: Ozempic presents a higher risk of low blood sugar, especially in diabetic patients taking additional glucose-lowering medications.
- Thyroid Tumor Warning: Both drugs carry boxed warnings regarding the potential risk of thyroid C-cell tumors, based on animal studies.
- Pancreatitis Risk: Individuals with a history of pancreatitis should exercise caution and consult their provider before starting either treatment.
From a tolerability perspective, Saxenda’s daily injections may reduce compliance compared to Ozempic’s once-weekly dosing, which many patients find more convenient. Additionally, some users report that Ozempic causes fewer gastrointestinal side effects, possibly due to the less frequent administration.
Regulatory and Practical Considerations
While both Saxenda and Ozempic belong to the GLP-1 receptor agonist class, their regulatory approvals and practical uses differ. Saxenda is FDA-approved for weight management, providing a clear indication for obesity treatment. Ozempic, although highly effective, is approved primarily for type 2 diabetes, with weight loss as a secondary benefit.
From a practical standpoint, the dosing schedule is a major differentiator: Saxenda requires daily injections, while Ozempic’s weekly regimen offers enhanced convenience for many patients.
It’s worth noting that counterfeit products of both drugs have been reported, particularly in the UK. Patients are strongly advised to obtain these medications only through legitimate healthcare providers and pharmacies to avoid serious health risks.
Conclusion
Although Ozempic offers greater weight loss benefits and a more convenient weekly dosing schedule, its lack of FDA approval for weight management may limit insurance coverage and access. Saxenda, while slightly less potent in terms of weight reduction, holds an FDA-approved indication for obesity and may be more accessible for those meeting clinical criteria.
The choice between Saxenda and Ozempic should be personalized, considering factors such as health status, medication tolerability, lifestyle preferences, budget, and treatment goals. Consulting with a healthcare provider is essential to determine which medication aligns best with your weight loss journey and overall health needs.
FAQs
1. What does Saxenda do?
Saxenda works for chronic weight management in adults with obesity or overweight who also have at least one weight-related condition.
2. How do practitioners administer Saxenda?
Saxenda is a daily subcutaneous injection. Practitioners typically inject it into the thigh, abdomen, or upper arm.
3. How much weight can I expect to lose with Saxenda?
Most people lose about 5-10% of their starting body weight over several months when combined with diet and exercise.
4. How long does it take for Saxenda to start working?
Some users may notice reduced appetite within a few days to a week, but significant weight loss usually takes several weeks.
5. Are there any common side effects of Saxenda?
Yes, including nausea, vomiting, diarrhea, and constipation. These symptoms are usually temporary and can be managed.
6. Who should not take Saxenda?
Individuals with a history of medullary thyroid cancer, pancreatitis, or multiple endocrine neoplasia syndrome type 2 should not use Saxenda.
7. Can Saxenda be used long-term?
Yes, it is intended for long-term use, provided it remains effective and well-tolerated under the supervision of a healthcare provider.
References
Madigan CD, Graham HE, Sturgiss E, et al. Effectiveness of weight management interventions for adults delivered in primary care: systematic review and meta-analysis of randomised controlled trials. BMJ. Published online May 30, 2022:e069719. doi:10.1136/bmj-2021-069719
Hartmann-Boyce J, Johns DJ, Jebb SA, Summerbell C, Aveyard P; Behavioural Weight Management Review Group. Behavioural weight management programmes for adults assessed by trials conducted in everyday contexts: systematic review and meta-analysis. Obes Rev. 2014;15(11):920-932. doi:10.1111/obr.12220